This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Cardiologist's View on the developing treatment landscape for resistant hypertension and the potential of Baxdrostat(CIN-107).

Ticker(s): CINC

Who's the expert?

Institution: HPMG

  • treats 50 patients with resistant hypertension
  • Board Certified Cardiologist working for the last 13 years as a non-invasive cardiologist
  • training focused on non-invasive cardiac imaging, echocardiograms, nuclear tests, Cardiac CT scans and Cardiac MRIs

Interview Goal
Discussing the potential of Baxdrostat (CIN-107),  a selective aldosterone synthase inhibitor for treatment of resistant hypertension in light of the recently announced positive topline data for it's Phase 2 BrigHtn Trial.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.